- Home
- TCRT vs SILO Comparison
TCRT vs SILO Comparison
Compare TCRT & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- SILO
- Stock Information
- Founded
- TCRT 1998
- SILO 2010
- Country
- TCRT United States
- SILO United States
- Employees
- TCRT N/A
- SILO N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- TCRT Health Care
- SILO Consumer Discretionary
- Exchange
- TCRT Nasdaq
- SILO Nasdaq
- Market Cap
- TCRT 7.0M
- SILO 8.0M
- IPO Year
- TCRT N/A
- SILO N/A
- Fundamental
- Price
- TCRT $2.84
- SILO $0.60
- Analyst Decision
- TCRT
- SILO
- Analyst Count
- TCRT 0
- SILO 0
- Target Price
- TCRT N/A
- SILO N/A
- AVG Volume (30 Days)
- TCRT 1.3M
- SILO 891.9K
- Earning Date
- TCRT 11-13-2025
- SILO 11-11-2025
- Dividend Yield
- TCRT N/A
- SILO N/A
- EPS Growth
- TCRT N/A
- SILO N/A
- EPS
- TCRT N/A
- SILO N/A
- Revenue
- TCRT $6,000.00
- SILO $72,102.00
- Revenue This Year
- TCRT $5,680,500.00
- SILO $1.86
- Revenue Next Year
- TCRT N/A
- SILO N/A
- P/E Ratio
- TCRT N/A
- SILO N/A
- Revenue Growth
- TCRT N/A
- SILO N/A
- 52 Week Low
- TCRT $1.31
- SILO $0.40
- 52 Week High
- TCRT $6.20
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- TCRT 49.53
- SILO 45.96
- Support Level
- TCRT $2.51
- SILO $0.53
- Resistance Level
- TCRT $3.16
- SILO $0.58
- Average True Range (ATR)
- TCRT 0.38
- SILO 0.06
- MACD
- TCRT -0.07
- SILO -0.01
- Stochastic Oscillator
- TCRT 16.02
- SILO 63.89
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.